

Table S1. The information of the melanoma patients for EphA2 analysis.

ID#	Mutation	site	rx	response (RECIST)	time to prog (months)
3	BRAF	sc	vemurafenib	SD (-10%)	10
15	BRAF	sc	vemurafenib	SD (-16.5%)	6
16	BRAF	sc, n	dabrafenib + trametinib	SD (-19.5%)	11
22	BRAF	lu, l, n	dabrafenib + trametinib	PR (-42%)	3
24	NRAS, BRAF	br, sc, lu, li, n	vemurafenib	PR (-53%)	2
25	BRAF	n, sc	dabrafenib + trametinib	PR (-64%)	3
26	BRAF	lu, sc, n	dabrafenib + trametinib	SD (-22.8%)	stopped drug after 2 months, PD at 2.5 months
34	BRAF	sc, n, br	LGX818 +MEK 162	PR (-48.6%)	stopped drug after 14 months, PD at 15 months